# Chemomab Therapeutics Ltd.: Form 20-F for the period ended Dec 31, 2023

- Company: [Chemomab Therapeutics Ltd.](/companies/cmmb.md) (CIK 1534248)
- Form: 20-F
- Filed: 2024-03-28
- Accepted by EDGAR: Mar 28, 2024, 06:03 ET
- Period: 2023-12-31
- Accession: 0001178913-24-001124
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1534248/000117891324001124/zk2431185.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1534248/000117891324001124/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2023-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Cost of revenue | 12 months, 2023-01-01 to 2023-12-31 | $4.4m | us-gaap:CostOfRevenue |
| Research and development | 12 months, 2023-01-01 to 2023-12-31 | $18.4m | us-gaap:ResearchAndDevelopmentExpense |
| Income tax | 12 months, 2023-01-01 to 2023-12-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months, 2023-01-01 to 2023-12-31 | −$24.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months, 2023-01-01 to 2023-12-31 | $0.10 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months, 2023-01-01 to 2023-12-31 | $0.10 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months, 2023-01-01 to 2023-12-31 | 234,998,859 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months, 2023-01-01 to 2023-12-31 | −$23.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months, 2023-01-01 to 2023-12-31 | $3.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2023-12-31 | $9.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2023-12-31 | $20.9m | us-gaap:AssetsCurrent |
| Total assets | at 2023-12-31 | $22.2m | us-gaap:Assets |
| Current liabilities | at 2023-12-31 | $4.8m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2023-12-31 | $5.2m | us-gaap:Liabilities |
| Shareholders' equity | at 2023-12-31 | $17.0m | us-gaap:StockholdersEquity |
| Shares outstanding | at 2023-12-31 | 284,094,700 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1534248/000117891324001124/zk2431185.htm

Filed Mar 28, 2024.
Source: SEC EDGAR, the filing index for accession 0001178913-24-001124. Last ingested by Listed: Nov 3, 2026, 08:33 ET. No prices; not investment advice.